Novel Small Molecule Adjuvants to Drug-eluting Stents
药物洗脱支架的新型小分子佐剂
基本信息
- 批准号:7395130
- 负责人:
- 金额:$ 29.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-02-15 至 2009-07-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAccelerationAdjuvantApoptosisBackBenchmarkingBinding SitesBiodistributionBiological AssayBiologyBlood VesselsC57BL/6 MouseCapitalCardiologyCell DeathCell ProliferationChemicalsClassClinicClinicalClinical TrialsCompatibleConsultCoupledCytoskeletonDataDepthDevelopmentDevice or Instrument DevelopmentDoseDrug DesignDrug effect disorderDrug usageEndothelial CellsEvaluationFibroblastsFutureGene ProteinsGoalsGrowth FactorGrowth Factor InteractionHeadHealedHemoglobinHepatocyte Growth FactorHumanHyperplasiaImplantIntellectual PropertyInternationalKentuckyKnowledgeLaboratoriesLawyersLeadLegal patentLibrariesManufacturer NameMediationMedicalMedical DeviceMedicineMorbidity - disease rateMyocardialNeoplasm MetastasisNumbersOperative Surgical ProceduresPaperPathway interactionsPeripheralPhage DisplayPharmaceutical ChemistryPharmaceutical PreparationsPhasePhase II Clinical TrialsPhysiologicalPlagueProtein ChemistryProteinsProteomicsProto-Oncogene Protein c-metPublishingRateResearchResourcesSafetyScientistSideSignal TransductionSmall Business Funding MechanismsSmall Business Innovation Research GrantSpecificityStagingStentsSurgeonSystemTechnologyTestingTherapeuticThrombosisTissuesTrainingTranslational ResearchTubeTyrosine Kinase DomainUniversitiesWisconsinangiogenesisbasecardiovascular injurycostdesignexperiencehealinghuman MET proteinin vivoin vivo Modelinterestlocal drug deliverymatrigelmedical schoolsmembermigrationmimeticsmolecular modelingmortalitynovelpharmacophorepre-clinicalprofessorprogramsrestenosisscaffoldsmall moleculesymposiumthree dimensional structuretoolvascular smooth muscle cell proliferation
项目摘要
DESCRIPTION (provided by applicant): Currently approved drug-eluting stents are plagued by late-stage thrombosis and delayed restenosis. Acceleration of stent re-endothelialization can suppress neointimal hyperplasia, promote healing of the vessel wall, and decrease restenosis rates. Scatter factor/hepatocyte growth factor (SF/HGF) promotes endothelial cell proliferation and migration. Feasibility of using an SF/HGF coat as an adjuvant on drug-eluting stents is compounded by issues relating to gene and protein therapy. Angion Biomedica is pursuing the development of small molecules that regulate SF/HGF/c-Met signaling to therapeutic advantage. Based on the 3-dimensional structure of the ATP-binding site of the SF/HGF receptor c-Met's tyrosine kinase domain and using a product discovery engine comprising phage display, 3-dimensional molecular modeling, protein chemistry and preclinical biology, we have identified a phthalazin-1 (2H)-one scaffold with potential SF/HGF-like bioactivity. Rational drug design-driven side-chain additions onto this scaffold led to the identification of Ang 1170, the first small molecule drug-like member within this class. Preliminary data indicate that Ang 1170 activates the SF/HGF/c-Met pathway, stimulates endothelial cell proliferation, and protects against endothelial cell death. Importantly, Ang 1170 has no effects on fibroblast or vascular smooth muscle cell proliferation. We have since constructed a structural library around the phthalazin-1 (2H)-one scaffold comprising 21 compounds with potential SF/HGF-like bioactivity, the eventual goal being the identification of an SF/HGF-like small molecule that is not only bioeffiacious and potent but also carries a safety profile compatible with human use. The goal of this Phase I application is to couple targeted proteomics and medicinal chemistry to an in vivo bioefficacy assay in order to identify lead and fallback candidates within this phthalazin-1 (2H)-one library for stimulation of the endothelial cell proliferation program. The two candidates emerging from this Phase I program will then be submitted to in-depth, preclinical SBIR Phase II studies comprising in vivo models of in-stent restenosis, biodistribution studies, and formal regulatory/safety studies. The ultimate goal of this study is to advance an SF/HGF-like small molecule to the clinic for use as an adjuvant coat on currently used drug-eluting stents.Late stage thrombosis and delayed restenosis plague currently approved drug-eluting stents and remains a significant cause of morbidity and mortality. A small molecule therapeutic that reduces restenosis has tremendous clinical benefit.
描述(由申请人提供):目前批准的药物洗脱支架受到晚期血栓形成和延迟再狭窄的困扰。加速支架再内皮化可抑制新生内膜增生,促进血管壁愈合,降低再狭窄率。分散因子/肝细胞生长因子(SF/HGF)促进内皮细胞增殖和迁移。使用SF/HGF涂层作为药物洗脱支架上的佐剂的可行性与基因和蛋白质治疗相关的问题复杂化。Angion Biomedica正在开发调节SF/HGF/c-Met信号传导的小分子,以获得治疗优势。基于SF/HGF受体c-Met酪氨酸激酶结构域的ATP结合位点的三维结构,并使用包括噬菌体展示、三维分子模拟、蛋白质化学和临床前生物学的产品发现引擎,我们鉴定了具有潜在SF/HGF样生物活性的酞嗪-1(2 H)-酮支架。合理的药物设计驱动的侧链添加到该支架上导致了Ang 1170的鉴定,这是该类中的第一个小分子药物样成员。初步数据表明,Ang 1170激活SF/HGF/c-Met通路,刺激内皮细胞增殖,并防止内皮细胞死亡。重要的是,Ang 1170对成纤维细胞或血管平滑肌细胞增殖没有影响。此后,我们构建了一个结构库,包括21个具有潜在SF/HGF样生物活性的化合物,最终目标是鉴定SF/HGF样小分子,其不仅具有生物有效性和有效性,而且具有与人类使用相容的安全性。该I期申请的目标是将靶向蛋白质组学和药物化学与体内生物功效测定相结合,以鉴定该酞嗪-1(2 H)-酮文库中的先导和后备候选物,用于刺激内皮细胞增殖程序。然后,将从该I期项目中获得的两个候选药物提交至深入的临床前SBIR II期研究,包括支架内再狭窄的体内模型、生物分布研究和正式的监管/安全性研究。本研究的最终目的是将SF/HGF样小分子推进临床,用作目前使用的药物洗脱支架的辅助涂层。晚期血栓形成和延迟再狭窄困扰着目前批准的药物洗脱支架,并且仍然是发病率和死亡率的重要原因。减少再狭窄的小分子治疗剂具有巨大的临床益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PRAKASH NARAYAN其他文献
PRAKASH NARAYAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PRAKASH NARAYAN', 18)}}的其他基金
PDGFR and KDR Inhibitors for Liver Fibrosis
PDGFR 和 KDR 肝纤维化抑制剂
- 批准号:
8833470 - 财政年份:2010
- 资助金额:
$ 29.55万 - 项目类别:
相似海外基金
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Continuing Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 29.55万 - 项目类别:
Standard Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
- 批准号:
23H01186 - 财政年份:2023
- 资助金额:
$ 29.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




